Insulet Corporation (PODD) exhibits 71.6% gross margins and 20.4% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 17.1x enterprise multiple and 4.8% implied options volatility.
Sustained 71.6% gross profitability converts into 17.5% operating margin and 20.4% ROIC, outpacing sector cost of capital.
ROIC: 20.4% // GM: 71.6%YoY revenue trajectory of +30.7% paired with 3.57% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +30.7% // FCF YLD: 3.57%Altman Z-Score of 5.72 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.72 // F-SCORE: 8/9Trading at 42.8x trailing P/E (36.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 42.8x // EV/EBITDA: 17.1xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $149.68 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 9.1% net margins.
NET MARGIN: 9.1% // D/E: 0.46x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for PODD & activate live FRED threshold breach alerts.